Neuroblastoma with high ASPM reveals pronounced heterogeneity and poor prognosis
ASPM holds promise as a novel biomarker for refining current risk stratification and predicting prognosis in neuroblastoma. Elevated levels of ASPM, LDH, and GLZLM_ZLNU may be associated with poorer survival outcomes in neuroblastoma patients.
Authors
- Suyun Chen (ORCID: https://orcid.org/0000-0002-6571-654X)
- Shuo Huang (ORCID: https://orcid.org/0000-0001-9495-4339)
- Chao Li (ORCID: https://orcid.org/0000-0002-0734-0011)
- Hui Wang (ORCID: https://orcid.org/0000-0002-0045-8797)
- Xueyuan Lu
- Fengxian Zhang (ORCID: https://orcid.org/0000-0002-6653-027X)
- Lin Ding (ORCID: https://orcid.org/0000-0003-4841-0183)
Institutions
- Tongji University (CN)
- Shanghai Jiao Tong University (CN)
- XinHua Hospital (CN)
- Shanghai Pulmonary Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1186/s12885-024-12912-4
- Citations
- 2
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.74
Funders
- National Natural Science Foundation of China